PTC Therapeutics

Founded in 1998, PTC Thereapeutics is a pioneer in the research and treatment of rare diseases such as Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase (AADC) deficiency, Huntington’s disease and spinal muscular atrophy. A Disease is considered rare if it does not affect more than five in 10,000 people. Many rare diseases are genetic and can be treated with gene therapy. Therefore, it is often crucial that rare diseases are diagnosed in early childhood.

Education and information, as well as exchange among medical specialists, are of great importance in the field of rare diseases. Life Science Communication supports PTC Therapeutics in communicating with physicians, with the technical and logistical organisation and implementation of specialist events in Europe and the Middle East.